NewAmsterdam Pharma (NAMS) appoints Adele Gulfo to Board

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the commercialization of multiple blockbuster medicines including LIPITOR^® and CRESTOR^®.

“We are delighted to welcome Adele to our Board of Directors at a critical juncture for NewAmsterdam, as we prepare for the potential launch of obicetrapib next year,” said Michael Davidson, M.D., Ph.D., Chief Executive Officer of NewAmsterdam Pharma. “Adele brings world-class commercial leadership and an exceptional track record of successfully launching blockbuster therapies on a global scale. Her strategic insight, mass-market drug launch experience and deep operational expertise will be instrumental as we work diligently to finalize our commercial strategy and build the infrastructure to support our first commercial launch, if approved.”

Most recently, Ms. Gulfo served as Chief Executive Officer for the Biopharma Commercial Unit at Sumitomo Pharma America, Inc., where she oversaw the commercial and development portfolio across various therapeutic areas, including oncology, rare disease, diabetes, urology, neurology, and women's health. Prior to Sumitomo, she was the Chief Commercial and Business Development Officer at Sumitovant Biopharma until its integration into Sumitomo Pharma America. Before joining Sumitovant, Ms. Gulfo served as Chief Commercial Development Officer at Roivant Sciences, where she played a key role in the formation of Sumitovant and led launch preparations for several major brands, such as ORGOVYX^®, GEMTESA^®, RETHYMIC^®, and MYFEMBREE^®. Earlier, Ms. Gulfo was the President and General Manager of Pfizer's U.S. primary care business unit, which generated over $12 billion in revenue. At Pfizer, she was Senior Director and Launch Lead for LIPITOR^®, which grew to a top-selling brand within two years of launch. Ms. Gulfo also served as the Country Manager for Pfizer's U.S. biopharma business, which encompassed specialty and oncology business units. Before joining Pfizer, Ms. Gulfo held multiple Vice President positions at AstraZeneca, including leadership of Commercial Readiness, Business Development, and the Cardiovascular Business Unit, where she successfully led the launch and growth of CRESTOR^® into a multi-billion-dollar brand.

In addition to her executive roles, Ms. Gulfo currently serves on the Board of Directors of Tyra Biosciences, a publicly traded biotechnology company, and Enpro, a publicly traded industrial technology firm. She is also a member of the Innovation Growth Board at Mass General Brigham, the largest hospital-based research enterprise in the United States. Ms. Gulfo holds a B.S. in Biology from Seton Hall University and an MBA in Marketing, with highest honors, from Fairleigh Dickinson University.

“I am thrilled to be joining NewAmsterdam Pharma’s Board of Directors at a transformational time for the Company,” said Ms. Gulfo. “NewAmsterdam Pharma’s progress to date is impressive, with successful execution and recent positive readouts from its three pivotal Phase 3 clinical trials. I believe NewAmsterdam is well on the path to making a significant impact on the treatment paradigm for patients at risk of CVD, and I look forward to partnering with the Board and executive leadership team as we drive forward the company's mission to improve the standard of care for CVD patients worldwide.”

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• PicPay integrates ChatGPT to let users query account data